D.E. Shaw & Co
MAZE

D.E. Shaw & Co’s Maze Therapeutics MAZE Stock Holding History

D.E. Shaw & Co’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$359K Sell
12,019
-33,617
-74% -$881K ﹤0.01% 4333
2026
Q1 		$1.36M Buy
45,636
+11,942
+35% +$527K ﹤0.01% 3199
2025
Q4 		$1.4M Buy
+33,694
New +$1.16M ﹤0.01% 3318

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

D.E. Shaw & Co's MAZE Position: Q2 2026 in Review

D.E. Shaw & Co reduced its Maze Therapeutics (MAZE) stake by 74% in Q2 2026, selling an estimated $881K and leaving 12,019 shares worth $359K. The position accounts for ﹤0.01% of the portfolio, ranked #4333.

D.E. Shaw & Co first reported a position in MAZE in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.4M in Q4 2025. 162 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • D.E. Shaw & Co held 12,019 shares of Maze Therapeutics worth $359K as of Q2 2026.
  • D.E. Shaw & Co sold 33,617 Maze Therapeutics shares in Q2 2026, an estimated $881K.
  • Maze Therapeutics made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #4333 holding.
  • D.E. Shaw & Co first reported a position in Maze Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • D.E. Shaw & Co's Maze Therapeutics position peaked at $1.4M in Q4 2025.
  • 162 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.